AcroCyte Therapeutics

AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination. AcroCyte is driving a revolution to make these advanced platforms a routine part of clinical practice—accessible, affordable, and impactful for patients worldwide.